Meeting
2023 ASCO Annual Meeting
Racial disparities in utilization of first line targeted therapies for metastatic breast cancer.
Authors
Yehoda M. Martei
University of Pennsylvania, Department of Medicine (Hematology - Oncology Division), Philadelphia, PA
Yehoda M. Martei , Kan Chen , Ronac Mamtani , Lawrence N. Shulman , Rebecca A. Hubbard , Amy Sanders Clark
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Health Services Research and Quality Improvement
Track
Quality Care/Health Services Research
Sub Track
Access to Care
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 6528)
DOI
10.1200/JCO.2023.41.16_suppl.6528
Abstract #
6528
Poster Bd #
20
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor SHR6390 combined with pyrotinib and letrozole in patients with human epidermal growth factor receptor 2-positive (HER2+), hormone receptor positive (HR+) metastatic breast cancer (MBC): Phase Ib study results.
First Author: Jian Zhang
Poster
2020 ASCO Virtual Scientific Program
Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2+/HR+ metastatic breast cancer.
First Author: Matthew Loft
Poster
2023 ASCO Annual Meeting
CAPTOR-BC: Comprehensive analysis of spatial, temporal and molecular biomarkers predicting response and resistance to first-line treatment with ribociclib + ET in HR+, HER2- advanced breast cancer.
First Author: Peter A. Fasching
Poster
2021 ASCO Annual Meeting
TRIO-US B-12 TALENT: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer.
First Author: Sara A. Hurvitz